



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Operations Office

TO: Principal Investigators and Primary Clinical Research Associates

FROM: Janis Wobschall
Protocol Development Coordinator

DATE: March 7, 2008

SUBJECT: N0272, Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma

Due to a number of calls regarding the status of this study, the following update is provided:

Study 1 is temporarily closed to accrual as of February 1, 2008.

Study 2 is currently open for accrual.

Study 3 is currently open for accrual.